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Abstract 
3D bioprinting technologies are rapidly developing and provide a platform for manufacturing structures 
that mimic the in vivo environment. Recent research aims to produce 3D bioprinted structures that 
recapitulate both in vivo structure and functionality. Advancements in both producing high fidelity and 
functional structures pave the way for full organ bioprinting. Full organ bioprinting holds promise for 
patients facing renal diseases given both the limited availability of donor kidneys for transplantation which 
offers the highest quality of life for patients facing renal failure. While the generation of a fully functional 
bioprinted kidney is a long-term goal, the first step is generating bioprinted functional renal tissue. 
Functional bioprinted renal tissue may pave the way for full scale organ printing and may offer a more 
accurate in vitro model for testing the renal toxicity of newly developed therapeutics which holds promise 
given the limitations of current preclinical in vivo and in vitro models to accurately predict renal toxicity of 
newly developed therapeutics in humans. Recent work showcases advancements toward renal bioprinting 
and advancements in the field of bioprinting more broadly may provide opportunities for advancement in 
renal bioprinting. This review aims to cover recent advances in renal bioprinting and opportunities for 
innovation. The review seeks to address the mechanical, biological and translational aspects of bioprinting 
functional renal tissue through an overview of recent advancements (last 5 years) in developing bioinks, 
utilizing existing 3D bioprinting methods to produce high fidelity printed structures, supporting viability, 
cell adhesion, cell distribution, functionality and vascularization, and considering important translational 




3D bioprinting involves the deposition of cell-laden bioinks to create 3-dimensional structures that replicate 
or mimic in vivo physiology. Although the advent of this technology has long been advertised as a solution 
to countless problems in regenerative medicine, the present-day state of bioprinting is far from generating 
patient-specific, functional organs. Regardless, the repetitive functional unit of the kidney makes it an 
attractive target for bioprinting, and there is a strong need for the development of functional renal tissue. 
One potential need is in organ transplantation. As of October 2020, over 83% of the 119,327 patients on 
the national organ transplant waitlist were awaiting a kidney transplant1. The average person placed on this 
list will wait over 3.5 years for a kidney transplant, requiring further treatment through dialysis and 
pharmaceuticals, and 13 of these people waiting for a transplant will die every day2. Kidney disease kills 
more Americans each year than prostate cancer or breast cancer3.  These numbers are expected to increase 
as the general population ages4. In addition to the lack of available donors, transplantation introduces 
complications in donor matching, shipping organs, and tissue preservation. Bioprinting entire or portions 
of kidneys could be an alternative method to organ donation for filling transplant needs. Another potential 
solution to this problem is prevention of kidney disease through bettering the current technique for 
determining drug renal toxicity. 3D bioprinting models using human cells more accurately mimic in vivo 
anatomy and physiology, providing a better screening platform for potential therapeutics before clinical 
trials begin. This could lead to a reduction in the 19-25% of acute kidney injury in critically ill patients 
caused by drug nephrotoxicity5. This number has been reported to be as high as 66% in elderly individuals6.  
A few common examples are: prerenal azotemia, the most common form of kidney failure in hospitalized 
people, can be caused by diuretics or vasodilators; immunosuppressants and anticoagulants have been 
linked to renal vascular injury; and various tubular injuries have been associated with antibiotics, 
chemotherapeutics, and other common clinical compounds7. In addition to saving countless lives, better 
renal toxicity models have the potential to drastically reduce the $10 billion spent annually in the United 
States on phase III drug trial human testing8. Nearly half of these phase III trials fail, and of those that fail, 
renal toxicity accounts for nearly 20%9. Improved renal toxicity models could improve in vitro drug testing, 
preventing more nephrotoxic compounds from reaching late stage trials. Currently, in vitro renal toxicity 
tests primarily focus on quantifying cell death of primary cultures or in animal models. However, these 
techniques are often inaccurate at predicting in vivo toxicity9,10. Why is bioprinting a promising solution to 
these problems? Alternative tissue engineering techniques such as electrospinning and soft lithography are 
not reliably reproducible, unable to accurately create anatomical microstructures like glomeruli, and 
homogeneous distribution of cells within scaffolds is more difficult to achieve.  Although attempts have 
been made to address these concerns, bioprinting through additive manufacturing is a more promising 
technique and has been used to reproducibly create multi-material constructs with high resolutions and 
homogeneous cell distributions at a relatively rapid rate11. The attractive properties of bioprinters have led 
to numerous advancements in tissue engineering.  Techniques have been developed enabling printing of 
multiple materials simultaneously12, homogeneously distributed-cell-laden constructs with high viability13, 
and anatomies from medical images14. Bioprinting has created implantable stents14, bone scaffolds15,16, skin 
tissue16,17, and neural cell-integrated muscle tissue18. Although the generation of full functional organs is a 
long-term goal, considering current advances in bioprinting, we propose a short-term goal of printing 
functional renal tissue. Functional renal tissue would mirror nephron structure; properly mimic the essential 
kidney functions of filtration, reabsorption, and secretion; and properly alter these functions in response to 
stimuli such as hypertension. This review serves to aim future research in the right direction to reach the 
goal of bioprinting functional renal tissue by comprehensively summarizing current literature on renal 
bioprinting and analyzing prominent literature in related fields with potential application towards the 
bioprinting of functional renal tissue.  
3. Background 
3.1 Kidney Physiology 
The repetitive nature of nephrons in kidney anatomy combined with the gradual loss of functionality 
experienced with kidney disease makes it an attractive organ for bioprinting19. Kidney function is 
oftentimes measured by glomerular filtration rate (GFR), which is the amount of blood that is filtered by 
the kidneys and can be calculated by multiplying the total number of nephrons in a kidney by the GFR of 
an individual nephron (GFR--nephron * # of functional nephrons --= GFRkidney)20. This indicates a linear 
relationship between kidney GFR and number of functional nephrons in the kidney. Studies have also found 
linear relationships between age and # of functional nephrons in a kidney as well as between number of 
functional nephrons and the progression of chronic kidney disease19,21,22. These losses of nephrons are 
accompanied with a corresponding reduction in GFR21,22. Once nephron loss reaches a critical amount, 
damage is irreversible and is then classified as end-stage renal disease, or kidney failure23. This linear 
relationship enables for the quantitative determination of kidney disease progression by measuring an 
individual’s GFR. Physiologically this means that the biological role of the kidney is equally divided 
between each of its ~860,000 nephrons22. This contrasts the physiology of other organs, such as the brain, 
heart, or intestines where functional unit physiology relies on where in the organ the unit resides. For 
example, an increase in blood pressure caused by increased water reabsorption in the kidney would be 
caused by a coordinated effort of each individual nephron increasing water reabsorption. This is critical in 
the pathophysiology of kidney disease as well as in the potential for renal bioprinting.  Following an initial 
renal injury, a small portion of nephrons are lost, which then increases the necessary filtration rates and 
blood pressure of other nephrons.  This induces nephron hypertrophy characterized by an increase in the 
size of glomerulus, Bowman’s capsule, and proximal tubule20. This size increase may be potentially harmful 
and can damage the layer of podocyte cells between the glomerulus and Bowman’s capsule which control 
blood filtration causing detachment, sclerosis of glomerular walls, and eventually nephron atrophy24–26.  
Continued nephron death further increases hypertrophy in remaining functional nephrons, which are then 
themselves at an increased risk to continue this cycle, further reducing global kidney function. The 
continuous mechanism of nephron-loss based reduction in kidney function may also point towards promise 
in bioprinting of renal tissue. Early identification and location could lead to partially replacing kidneys 
during early stages of chronic kidney disease, preventing disease progression and reducing the nearly $1 
trillion annually spent on end stage renal disease worldwide28. If detected in later stages, upon development 
of a method to reliably print functional renal tissue, bioprinters could be used to customize an implant to 
replace any section of damaged kidney tissue to restore healthy kidney function and prevent progression to 
end-stage renal disease. For more information on the specific pathophysiology of chronic kidney disease, 
or early stages of chronic kidney disease, these two reviews are excellent resources20,27. 
3.2 Existing Clinical Options 
The development of a bioprinted kidney would be advantageous since current clinical options fall short. 
Current clinical options for treating chronic kidney disease include transplant, hemodialysis, and peritoneal 
dialysis. Additionally, recent research has focused on producing wearable artificial kidney devices which 
perform dialysis functions in mobile unit. Deceased or living donors may provide the kidneys for 
transplantation. The five-year survival rate of transplant of patients who received deceased donor kidneys 
was approximately 79%, and the five-year survival rate of patients who received living donor kidneys was 
approximately 87% in 2018 based on unadjusted Kaplan-Meir analysis of patients who received a kidney 
transplant in 201328. While transplantation can treat patients with renal failure, the treatment is limited by 
the availability of donor organs and allograft rejection may result despite tissue typing and immune 
suppression. Despite these limitations, organ transplantation offers kidney failure patients with the highest 
quality of life of the existing clinical options. With organ transplantation, a donor kidney takes on the 
functions of the patient’s failed kidney; in contrast, dialysis does not provide a cure and instead is only a 
management strategy for the chronic disease. While dialysis methods may act as a substitute for native renal 
filtration and can prolong a patient’s life, none of the existing dialysis options  restore full native kidney 
functionality.  
One of the earliest developed renal failure treatments is hemodialysis which was first applied successfully 
in 194529 and remains the most common treatment for chronic renal failure globally30. In hemodialysis, an 
external machine filters a patient’s blood. The hemodialysis system is based around a dialyzer which 
separates blood from a dialysate with a semipermeable membrane30. Based on the solute composition of 
the dialysate which can be tuned by the dialysis administrator, small waste solutes will pass from the 
patient’s blood across the semipermeable membrane into the dialysate, and the newly filtered blood is 
returned to the patient. While hemodialysis can effectively filter blood, significant limitations exist. Most 
patients must travel to a dialysis center three times a week and each session takes approximately four 
hours31.  Alternatively, approximately 12% of hemodialysis patients receive home dialysis. While home 
dialysis eliminates the need for travel to a center, it requires extensive training and many patients require a 
caretaker to assist with the dialysis32. Furthermore, hemodialysis has poor long-term survival rates. In 2017 
the hemodialysis mortality rate was approximately 17% based on the 2019 United States Renal Data 
Systems Report33. 
An alternative to hemodialysis is peritoneal dialysis. In peritoneal dialysis, the patient’s peritoneal 
membrane, the serous lining of the abdominal cavity, is used as a semipermeable membrane instead of a 
synthetic external semipermeable membrane as in hemodialysis. There are two major types of peritoneal 
dialysis: continuous ambulatory dialysis (CAPD) and continuous cycling peritoneal dialysis (CCPD). In 
CAPD a catheter is used to fill a patient’s abdominal cavity with dialysate and the dialysis fluid is allowed 
to dwell in the patient as solute exchange occurs between the patient’s blood and the dialysate. The fluid is 
exchanged between an external dialysate bag, the patient’s abdomen, and an external collection bag three 
to four times during the day and once overnight. As opposed to hemodialysis, CAPD occurs passively 
during the course of a patient’s routine34. In CCPD, an automated style of peritoneal dialysis, a device called 
a cycler automatically fills and drains the patient’s abdominal cavity with dialysis fluid. The exchange is 
performed three to four times overnight and once during the day. In a study of patient opinions of peritoneal 
dialysis, 94% of a cohort of 2760 randomly sampled respondents from seven countries between 2014 and 
2017 categorized the ability to receive treatment from home as a major advantage35. The most frequently 
listed disadvantages by the cohort were experiencing a bloated feeling during treatment and the storage 
space required by peritoneal dialysis supplies35. Additionally, patients undergoing peritoneal dialysis are at 
risk of peritonitis, a potentially life-threating infection that often results from contaminated catheter 
insertion36. In addition to an increased risk of peritonitis, CCPD-related increases in intra-abdominal 
pressure cause increased rates of abdominal wall complications such as hernias 37.  
Wearable artificial kidneys (WAK) may potentially offer an improved solution to chronic kidney disease. 
WAKs are devices that perform hemodialysis, peritoneal dialysis, or a combination of the two techniques 
in a mobile fashion. A WAK filters a patient’s blood with an artificial semipermeable membrane or the 
patient’s peritoneal membrane in a wearable lightweight device, and the WAK also regenerates the 
dialysate, permitting continuous mobile filtration38. Unlike dialysis methods which are common clinical 
options, no WAKs have received FDA approval to date. One major obstacle to commercially available 
WAKs is the removable of toxins without the large volumes of dialysate required for traditional dialysis 
methods. Current research aims to reduce the amount of dialysate required through recycling used dialysate. 
Dialysate can be regenerated using sorbents, which bindtoxins in the dialysate removing them from the 
body39. Common sorbents include activated charcoal10 and zirconium phosphate40,41.  Additionally, since 
the most commonly used sorbents fail to adsorb urea, WAKs may incorporate a urease column for the 
enzymatic elimination of urea4213 or rely on electro-43 or photo oxidation44 to eliminate urea waste.  
3.3 Need for Renal Bioprinting 
There is a definite need to address the limitations of transplants and dialysis methods. Transplantation is 
limited by donor organ supply and risk of allogenic rejection, and dialysis methods filter patient’s blood 
but are dependent on cumbersome external equipment. Whole organ bioprinting may one day provide 
patients with substitute kidneys that recapitulate native tissue function. However, additive manufacturing 
of a full transplantable kidney has not yet been realized. The generation of bioprinted kidneys will require 
significant advances in large-scale vascularized organ bioprinting. A successfully bioprinted kidney will 
mimic the mechanical and cellular aspects of the native kidney. 
3.4 Challenges in Whole Organ Bioprinting 
Whole organ bioprinting involves depositing heterogenous cell types and scaffold to create in vivo scale 
synthetic organs.  Several challenges have limited the translational potential of whole organ bioprinting. A 
transplantable bioprinted kidney will need to possess mechanical and biological characteristics that mimic 
the native kidney.  To address biological considerations the material must support cell adhesion, viability, 
and native functionality. Mechanical properties are dependent on the selected bioink as well as bioprinting 
method. Bioinks will need to be developed that provide mechanical support and support biological function. 
Since organs such as the kidney are heterogeneous in structure, the printing of complex gradients of 
materials and bioactive cues will be required. However,the field of developing complex heterogeneous 
bioinks is still its infancy45. Additionally, the selected bioprinting method must support high resolution 
printing to recreate delicate organ structures such as the kidney’s tubular network46. 
Another challenge is sourcing the cells to create a real-size printed organ. The large number of cells that 
will not illicit an immune required for organ printing often cannot be obtained from autograft alone, and 
instead in vitro expansion will be required. Primary cell lines have limited expansion potential because 
higher passage cells may not exhibit native behavior. For example, at greater than three passages, renal 
tubular cells exhibited senescence47. 
Solid organs such as the kidney pose unique biological challenges for bioprinting. For example, the 
translation of small in vitro bioprinted structures to full-size adult organs will require the creation of a 
vascularized network so that nutrients and wastes can be exchanged deep within the printed construct to 
avoid cell death at the core48. Current advances in inducing or creating vascularized printed tissues that may 
be leveraged in renal bioprinting include using blend bioinks49, incorporating gelatin microparticles to 
create porous microstructures50,  incorporating angiogenic growth factors such as vascular endothelial 
growth factor51,52, and microchanneling53. 
To meet these challenges, full organ kidney bioprinting will require leveraging existing advances made in 
bioprinting and pioneering methods to address the current limitations in whole-organ additive 
manufacturing. 
This review serves to aim future research in the right direction to attain the goal of bioprinting functional 
renal tissue.  To do this, the review will cover problems faced in renal bioprinting, and propose different 
methods to solve them.  In writing this review, we will include research on development of the bioinks 
useful in renal bioprinting and their corresponding print structure; the incorporation of cellular aspects such 
as viability, adhesion, cell distribution, functionality, and vascularization; and the translational aspects of 
bioprinting renal tissue including larger-scale printing, clinical potential, and prospects towards whole 
organ generation. We expect our limits of research to be defined by a comprehensive assessment of all 
recent (past 5 years) advances in renal bioprinting as well as potentially applicable advances in non-renal 
bioprinting technology.  
 
4. Recent Advancements  
4.1 Printing Structure  
The final printed structure is dependent on the printing method selected and the determines in part the 
structural fidelity and mechanical performance of the final printed construct. Advances in kidney 
bioprinting showcase some of the early attempts at solid organ bioprinting which faces a unique set of 
challenges.   A printed construct should support mechanical stresses likely to be placed on the construct 
when implanted in vivo while maintaining porosity necessary for waste and nutrient perfusion. Three main 
methods of 3D bioprinting, extrusion-based, laser-based and droplet-based, exist, each with different 
advantages and disadvantages as we look toward full functional kidney bioprinting.54 
4.1.1 Extrusion-based Bioprinting  
Extrusion-based bioprinting involves pressure or a mechanical plunger to extrude a biomaterial. Extrusion-
based bioprinting has been used to print a wide variety of biological structures including but not limited to 
cardiac55, liver56, and cartilage57 tissue engineering. Advantages of extrusion-based bioprinting include the 
ability to print porous scaffolds and soft materials.58 However, one primary disadvantage of extrusion 
bioprinting techniques is that lower resolution is possible than can be achieved with other techniques, and 
strategies for increasing resolution such as reducing nozzle size may place additional shear stresses on the 
cell in the bioink reducing post-printing viability. Higher resolution extrusion-printed structures have been 
achieved with the freeform reversible embedding of suspended hydrogel (FRESH) bioprinting 
technique.59 With the FRESH technique the soft biomaterial is extruded into a microparticle bath that 
provides support until the material can be crosslinked into a solid structure. With the FRESH technique 
resolution has been shown to be a linear function of nozzle diameter with printed resolution ranging from 
20 μm to 200 μm for needles with diameters from 10 μm to 200 μm (R2=0.97). The high resolution 
achieved with soft biomaterials through FRESH printing is promising for printing high fidelity structures 
such as kidney nephrons. Since soft biomaterials will likely be used to bioprint kidneys, extrusion-based 
bioprinting is a promising technique.  
4.1.2 Droplet Based  
Droplet-based bioprinting is a technique that uses inkjet, acoustic-droplet-ejection or micro-valve 
technology to deposit a series of droplets to form biomimetic structures.60 Advantages of droplet-based 
bioprinting involve potential to produce heterogenous patterns of cells and biological factors. For example, 
droplet-based bioprinting has been used to print high-resolution interfaces of human embryonic kidney cells 
and mesenchymal stem cells.60  Such advancement paves the way for generating a heterogenous 
multicellular full-scale bioprinted kidney. However, distinct limitations of droplet-based bioprinting exist. 
Due to limited range of droplet-based bioprinting suitable bioinks it is difficult to produce large and 
structurally stable constructs.7  
4.1 Laser-based Bioprinting and Stereolithography  
Laser-based bioprinting and stereolithography both utilize light to produce 3D-bioprinted constructs. In 
laser-based bioprinting, a focused laser is used to direct the deposition of a bioink a droplet-by-
droplet fashion. Laser-based bioprinting allows precise printing with a non-contact nozzle free 
approach.61 Laser-based bioprinting has been used to bioprint dermal tissue62, cornea-mimicking 
structures63, and many more biological constructs. However, laser-based bioprinting is limited by increased 
manufacturing time compared to other methods and decreased cell viability in printed constructs.64 On the 
other hand, stereolithography involves using a light source to solidify layers of light sensitive materials, 
building structures in a layer-by-layer fashion. Stereolithography has the highest accuracy of the methods 
discussed.61 Stereolithography is limited by the paucity of biocompatible light sensitive biomaterials as 
many developed have toxic byproducts and the technique does not permit the formation of horizontal 
gradients reducing the complexity of materials that can be generated.65 
4.2 Current Bioinks Used in Renal Printing  
Full organ bioprinting requires selection of an appropriate bioink. A bioink is a cell-laden 
biomaterial deposited by the selected printing method. All bioinks used in renal bioprinting must meet three 
distinct criteria: 1) compatibility with selected printing method 2) desirable post-printing mechanical 
properties 3) biocompatibility. A fibrinogen and gelatin bioink for 3D printing renal structures has been 
developed by the Lewis group that meets these criteria.66 The fibrinogen bioink was fabricated to include 
the enzymes thrombin and transglutaminase which permit the solidification of the bioink. The thrombin 
converts fibrin to fibrinogen while transglutaminase more slowly crosslinks gelatin with fibrinogen to fuse 
printed layers together. A fugitive ink that liquifies when cooled was used to form hollow tubule structures. 
This bioink supported renal cell viability and functionality. The Atala group recently developed 
an methacrylated decellularized kidney ECM-derived bioink, KdECMMA, for printing renal 
tissue.67 The bioink possessed key functional properties including a viscosity that prevents cell settling, 
shear thinning behavior to prevent cell damage during extrusion, and rapid photoinitiated crosslinking post-
deposition. Furthermore, the material supported enhanced cell proliferation compared to a gelatin only 
control (P < 0.05).67 Additionally, a San-Diego biotechnology company, Organovo, working in 
collaboration with the Murdoch Children’s Research Institute,  published a preprint showcasing the 
development of a cell-only paste that can act as a bioink for printing renal organoids.68 Figure 
1 showcases all reported bionks used at the time of this review used for renal bioprinting. The limited list 
of bioinks described here reflects the infancy of the field of renal bioprinting. 3D-dimensional renal cell 
culture is presently a more established field than renal bioprinting and showcases materials that may be 
adapted for 3D bioprinting.  
 
Figure 1: A. Gelatin / fibrin bioink used to print proximal tubule structures by the Lewis Group. 
B. kdECMMA bioink used to print tubular and glomerular structures by the Lee group. C. Cell 
only bioink used to print kidney organoids by Organova.  
 
4.3 Current Biomaterials Used for 3D Renal Cell Culture and their Potential as Bioinks  
The following referenced papers show promise in 3D renal cell culture and may be aptly suited for 
bioprinting. Recently a novel heparin-based PEG-star hydrogel was shown to promote human 
renal tubulogenesis in vitro. Similar multi-armed PEG based hydrogels have been 
previously bioprinted showing potential of for the heparin-based material as bioink69; however, further 
material characterization would be necessary to determine if the heparin modified material possesses the 
rheological and post-printing characteristics required for a bioink. Additionally, collagen hydrogels have 
been shown to support the formation of renal structures.70, 71 Collagen has served as a bioink for many non-
renal bioprinting applications including to generate high resolution structures using the FRESH bioprinting 
technique.55 Furthermore, many ECM-derived biomaterials have been used to support 3D renal cell culture 
and could be adapted to serve as bioinks as shown by the Atala group.72, 73, 74, 75 See the review here for a 
more complete overview of bioinks for bioprinting.76 
4.4 Cell Adhesion  
To maintain functionality of the printed scaffolds before the structures are perfused with media, cell 
attachment to the printed material must occur. Some naturally derived bioinks promote cell adhesion 
without modification.  For example, Yeong et al showed primary kidney cell adhesion to a decellularized 
porcine ECM scaffold.77 Additional, tissue engineering applications have shown natural renal cell adhesion 
to ECM-derived biomaterials.67,72-75,77 Furthermore, fibrin78 and collagen55,71 biomaterials have been 
shown to support renal cell adhesion. If synthetic materials, such as PEG, are used as bioinks, additional 
factors may need to be added to the materials to promote cell adhesion. A common technique to increase 
cell adhesion to non-adherent biomaterials such as PEG is modification of the synthetic polymer with cell 
adhesion promoting peptide sequences such as RGD.79 
4.4 Cell Distribution  
3D bioprinting of a full functional kidney will require printing multiple cell types in an organized 
distribution to mimic native cell arrangement; however, the bioprinting of multiple kidney cell types has 
not yet been realized. A functional kidney construct will feature a complex arrangement of cell types as 







Figure 1: Hematoxylin and eosin staining of the kidney shows the complex arrangement of heterogenous 
cell types forming renal structures including the glomerulus, cortex and medulla. (Image from University 
of Nottingham.80)  
 
While multiple cell types have not been printed for renal tissue engineering. Current advances in bioprinting 
showcase heterogenous cell type bioprinting for applications such as cardiac and urethra tissue engineering 
where similar techniques may one day be applied to printing renal structures. For example, multicellular 
heart tissue has been bioprinted by using multiple microfluidic pumps.81 Additionally, multicellular urethra 
tissue was printed using the integrated organ printing technique (IOP).82 IOP manufacturing uses 
multiple pressure-controlled cartridges with each connected to a microscale nozzle.83 Furthermore, Liu et 
al demonstrated that it was possible to fabricate constructs with up to four cell types using a 
novel multimaterial extrusion bioprinting platform.84  
4.5 Cell Viability  
In addition to creating a print structure with high resolution and print fidelity, bioprinted structures must 
also be able to sustain cell viability throughout the entirety of the bioprinting process and during subsequent 
culture. During the printing process, shear stresses and extensional stresses caused by needle extrusion 
of bioinks are the primary cause of decreases in cell viability.85 Factors that decrease stresses such as 
increasing the print nozzle diameter, decreasing bioink viscosity, and decreasing print pressure have been 
found to increase cell viability post-print.86,87,88 The opposite effect is found in print fidelity and accuracy. 
When nozzle size increases, pressure decreases, and viscosity decreases, print accuracy and fidelity 
decreases.87 Nair et. al. developed models to predict the proportions of live, injured and dead cells as a 
function of both pressure and nozzle diameter.86 Other groups have measured or created models predicting 
cell viability of different cell lines based on quantifications of shear stresses or extension stresses in 
bioprinting.85,88 A promising method to achieving relatively high print fidelity while also maintaining strong 
cell viability is FRESH bioprinting.59 This method suspends bioinks of interest in a secondary hydrogel 
bath, enabling printing of low-viscosity shear-thinning hydrogels with high accuracy. Following the 
printing of the bioinks, due to the 3-dimensional structure of renal tissue, ample nutrient supply to all 
portions of the structure is critical for maintaining high cell viability throughout culture and tissue 
development. Without ample nutrient delivery, cell viability, specifically in the center of the scaffold, may 
decrease due to hypoxia-induced apoptosis.89,90 Within renal bioprinting, the supply of growth factors to 
induce proper differentiation of stem cells is also crucial in future creation of anatomically and 
physiologically accurate tissue.  A promising approach to short-term nutrient supply to cells throughout 
a bioprinted scaffold was summarized in a recent paper where a Ge1MA gel is printed simultaneously with 
a gelatin sacrificial gel. Upon photo-crosslinking the Ge1MA gel, the gelatin is washed away, allowing for 
nutrient diffusion throughout the gel and high cell viability throughout the bioprinted structure.91 Ouyang 
et al. optimized print parameters for HEK293 cells and achieved nearly 95% post-extrusion viability at 
room temperature, long-term stability, and normal biological functions of these cells by printing 
a macroporous structure.92 However, it was noted that shear-stresses caused a reduction in cell viability and 
beyond one month cell viability decreased. The authors hypothesized this was due to lack of proper nutrient 
diffusion.9 Potentially by combining these optimal print properties with the sacrificial gel through FRESH 
printing, the cell viability could be even further improved as well as an increase in structural integrity and 
long-term nutrient diffusion. It is also worth noting that cell viability has been shown to increase when 
cultured in three-dimensions or when renal tubule cells polarize and participate in vascular-endothelial 
cross-talk characteristic of nephrons.93,94 
4.6 Functionality  
To date, most attempts at recapitulating nephron physiology in vitro aim at creating a functional proximal 
tubule. This is because the proximal tubule is the most damaged site in kidney injury, making it a target for 
nephrotoxicity studies, as well as being the site of 65-80% of nutrient reabsorption into the 
bloodstream.66 Typical proximal tubule function is characterized by uptake across the apical membrane and 
exit from the cell across the basolateral membrane.95 The capability of membrane transport is visible in the 
polarization of human kidney cells, where certain organelles and transporters localize to either the 
basolateral membrane or the apical membrane depending on their function. Specifically, mitochondria tend 
to be more heavily concentrated on the basolateral side of the cell where golgi bodies tend to gather on the 
apical side of the cell.96 Primary attempts to artificially mimic renal tissue function begin here, and these 
morphological characteristics in addition to responses to nephrotoxins, hyperglycemic or hypersaline 
conditions are oftentimes used to quantify the success of such attempts. Numerous hydrogels have been 
found that induce tubulogenesis or renal function in vitro. It was found that a photo-crosslinkable porcine 
ECM hydrogel combined with gelatin, hyaluronic acid, and glycerol for rheological properties contributed 
to elevated viability, polarity, and amino acid transfer in a non-structured hydrogel.67 Furthermore, the 
solubilized ECM induced immunohistochemical-analyzed tubulogenesis significantly better than a gelatin 
methacrylate gel.67 Similar successes were also observed with a synthetic four-armed maleimide 
polyethylene glycol hydrogel with optimized conditions, providing an alternative to xenogenic ECM 
hydrogels.97  Another study found that a heparin-based hydrogel induced tubulogenesis with consistent 
morphology and architecture to native tissue. These cells also showed organic ion transfer and proper 
response to nephrotoxins.96 Many attempts have been made to mimic proximal tubule function in 
vitro without bioprinting in order to better nephrotoxicity testing in clinical trials.93,94 By creating adjacent 
linear microchannels, vascular-endothelial cross-talk was able to be replicated. They found that the 
polarization and biomarker expression of human kidney cells increased in a 3D culture as well as their 
viability.93 Also, sodium-coupled glucose transport, albumin uptake, and intracellular enzyme function was 
replicated in addition to significantly higher cell count when kidney cells were cultured adjacent to 
endothelial cells (p<0.001). 93,94 Although these systems are able to recapitulate functionality of the 
proximal tubule, the ability to create larger functional tissues or organs is limited due to the inability to 
customize curvature, size, and shape of the nephron portions due to the fabrication technique.  Considering 
these limitations, bioprinting is a convenient solution to this issue, as similar techniques can be used to 
create customizable tubular architectures. The Lewis lab at Harvard University has been able to successfully 
combine the successes in microfluidic systems and the advantageous nature of bioprinting to rapidly print 
functional proximal tubule architectures for cell seeding.66,98 The process involves the deposition of ECM-
derived hydrogels over a sacrificial gel printed to the custom shape of the proximal tubule.  After dissolution 
of the sacrificial gel, PTEC-TERT1 cells are able to be cultured in the microchannels to confluency. The 
initial tests showed this model, similarly to the other microfluidic systems, was able to properly model cell 
polarization as well as albumin uptake and response to nephrotoxins. These tubules were viable for the 
entirety of the 65-day tests.66 In subsequent publications, vascular channels were able to be printed 
adjacently to tubular channels, enabling albumin uptake as well as glucose reabsorption based on external 
signals.98 This bioprinting method shows promise towards the fabrication of larger quantities of proximal 
tubules and accompanying vasculature. Beyond immediate function, innervation may be a difficult task in 
functional renal tissue generation.  In muscle tissue, it was found that mixing neural stem cells with 
the bioprinted muscle progenitor cells in a 1:300 ratio increased muscular generation, long-term viability, 
and was able to generate more force than the muscle cell only model 8 weeks after implantation 
(p=0.047).99 Similar techniques could be applied to renal tissue, enhancing function, integration into the 
host nervous system, and long-term cell viability of tissue structures.  
4.7 Vasculature  
As previously stated, a primary hurdle faced in larger scale tissue engineering is sustaining long-term 
nutrient delivery and waste elimination through functional vascular networks. Without this development, 
living bioprinted tissue has a limit of a few hundred micrometers in thickness.100 Although microchannels 
are able to support cell viability immediately after printing, as printed cells proliferate and differentiate, 
secreted ECM fills the hydrogel, hindering the ability for microchannels to ensure nutrient delivery inside 
the scaffold. In a similar fashion to functional proximal tubules, bioprinting of vascularized tissue typically 
involves the printing of multiple hydrogels, followed by the washing away of a sacrificial gel, leaving 
microchannels where vascular endothelial cells can be cultured. Commonly used sacrificial gels include 
Pluronic F-127, carbohydrate-glass, gelatin, and agarose.101 Early developments and printing of 
microchannels occurred used FRESH printing and similar methods.102,59 Hinton and colleagues used 
FRESH to print an MRI-derived coronary artery system with <15% variability in dimensions. 
59 Approximately the same time, Bhattacharjee et al. used Carbopol hydrogels and local injections to reach 
similar accomplishments, printing hierarchically branched networks with diameters in the 100um range was 
able to seed cells into these microchannels.102 With more general applications, sacrificial writing into 
functional tissues (SWIFT) printing suspends grouped iPSC’s, termed embryonic bodies and organ building 
blocks, into ECM and Matrigel hydrogels before using bioprinters to inject sacrificial ink into microchannel 
locations of interest. Using this technique, a microchannel was developed, and media was used to 
differentiate iPSC’s into cardiomyocytes, which developed a synchronous beat following 7 days of culture. 
The authors do note cell confluency was difficult to achieve. This technique could be applied to differentiate 
autologous iPSC’s into epithelial and renal cells to create sustainable vascularized renal tissue.19 The Lewis 
lab was also able to achieve similar results in osteogenic tissue engineering. Multi-material bioprinting was 
used to create cylindrical vessels with elastic walls printed into a mesenchymal stem cell and neonatal 
dermal fibroblast hydrogel. Confluency was observed and viability was sustained for 6 weeks. Thick tissues 
were developed by creating multiple vessels, which were able to maintain cell viability throughout 1cm 
thick tissues.103 Attempting to demonstrate the accuracy of their microchannel printing method, Grigoryan 
et al used tartrazine food dye in a photopolymerizing gel to bioprint functioning alveolar vasculature. 
Oxygen transport was observed in this model by quantifying blood oxygen level before and after alveolar 
interaction. Most notably, as alveolus and glomerular sizes are roughly equivalent, similar techniques could 
be adapted to model glomerular filtration in vitro.104 A final approach to printing vasculature in tissue 
constructs is the use of coaxial printing, where vascular endothelial cells are printed through the same nozzle 
as tissue-specific cells with a sacrificial gel. This approach eliminated the need for cell perfusion into the 
scaffold and instead showed strong confluency of cells in vessels by simply perfusing tailored media into 
the scaffold.  Furthermore, heterogeneous structures with multiple cell types are able to be printed through 
the same print nozzle, enabling the printing of heterogeneous cell structures. This method was applied with 
success to both osteogenic and cancer tissue, however relatively low cell viability was achieved with only 
~80% of cells being viable following printing and after culture.105 It has been shown that large-scale 
vascular networks can be developed, challenges moving forward include development of blood vessels with 
sub 100um diameters, integrating tissue function and vasculature, and maintaining high cell viability in 
more developed tissue constructs.  
4.8 Towards Large-Scale Tissue Bioprinting  
As many of the studies highlighted in this review focus on bioprinting of structures <1cm in length, 
significant advances in bioprinting must occur before whole-organ printing is realized.103 Although one 
work estimated the ability of their technique to be upscaled to nearly 100mL hydrogels, at this scale, the 
sourcing of such large quantities of, in that specific case, iPSCs is another obstacle to overcome in 
itself.100 Furthermore, as scaffolds grow in size, cell viability may also decrease.105 If taking the approach 
established by Lin et al where sacrificial inks are utilized for tubule development,98 preserving accurate 
tubule structures throughout the extensive time frame printing would occur followed by preservation of 
channels and accurate placements of heterogeneous cell types using perfusion are all much more difficult 
to obtain on a larger scale. Coaxial printing may hold the key to printing heterogeneous cell types but 
maintaining cell viability during printing as opposed to perfusion may prove challenging. However, 
promising progress has been shown in printing vascular channels and upscaling this process may overcome 
problems in nutrient supply and waste removal. With regards to future manufacturing, customizable kidney 
morphologies for implantation would require methods to create personal CAD models, which would 
require MRI scans to be converted to printable files with both accurate structures and cell types. A method 
may need to be developed to accomplish this conversion from medical imaging to printable files. In short, 
print fidelity and structure upon upscaling of these methods and accurate culture and deposition of 
heterogeneous cell types at a scale which is magnitudes larger than currently shown are major challenges 
that need to be addressed.  
4.9. Renal Bioprinting in Clinical Applications  
To achieve the bioprinting of transplantable kidneys in a clinical setting, added challenges include 
maintaining structure and viability during transportation of tissue following biofabrication; integration into 
the patient’s nervous, circulatory, and excretory system; and ensuring long-term function and stability post-
implantation. Transportation may be solved through supplying surgical hospitals with bioprinters or 
through implementing similar techniques to retain tissue viability currently used in transplantation.  In 
vivo studies of muscle implants in murine models successfully accomplished integration with host nervous 
systems through mixing low concentrations of neural stem cells into bioinks.99 For vascular integration, a 
technology termed the AngioChip accomplished anastomosis in rat models using connection through 
surgical cuffs, observing native angiogenesis a week following implantation.106 Similar surgical methods 
could be used to attach the much larger renal collecting duct to ureters for waste excretion. Finally, long-
term stability and immunogenicity in the patient are critical for developing medical technologies that meet 
standard of care. To achieve this, autologous iPSCs could be used to prevent the ethical considerations and 
variability of other stem cells as well as reducing transplant immunogenicity as cells would be sourced from 
the patient. This approach was used by Skylar-Scott and colleagues while bioprinting of vasculature using 
the SWIFT method.100 Additionally, to print larger full organ structures it will be critical to amplify suitable, 
ideally autologous, cell sources to produce sufficient scaffold cell confluency. For more complete guidance 
on use stem cells in tissue engineering we direct readers to the review here.107 
5. Conclusion 
In this text, recent research on renal bioprinting is discussed. Rapid advancements are being made 
towards being able to print three-dimensional renal tissue. Both synthetically and naturally derived 
bioinks have been developed with the ability to mimic natural kidney mechanical properties as well as 
achieve high cell viabilities, stimulate cell adhesion, and maintain shape fidelity. Furthermore, bioprinting 
techniques have achieved the resolution required to accurately replicate renal tubular architectures 
including glomeruli, tubules, and corresponding blood vessels. The ability to print these structures has 
been combined with cell-seeding techniques in order to create functioning blood vessels, recapitulating 
proximal tubule-arteriole cross talk, showing the ability to alter absorption in response to external stimuli. 
These models can better predict nephrotoxicity than simple culture of compounds of interest with kidney 
cells. Furthermore, techniques utilizing sacrificial gels have printed complex vascular networks, enabling 
the bioprinting of anatomically relevant thick tissues. Beginning work has shown promise in neural, 
tubular, and vascular host integration as well. Despite these advances, sizable progress is required to 
realize bioprinting as a platform for creating functional renal tissue. First, a primary need in renal 
bioprinting research is the ability to source, culture, and properly print large enough cell quantities to 
create tissue structures capable of implant. Secondly, although individual proximal tubules have been 
developed, and alveolar structures could match glomerular structures, the bioprinting of a single nephron 
with all functional parts has not yet been achieved, this could be the next step in bioprinting fully 
functional tissue. A potential obstacle in this process using existing techniques is the differentiation in 
physiology between proximal and distal tubules. In addition to creating entire nephrons, functional tissue 
would require multiple nephrons working together to filter blood and collect filtrate for urine production. 
To the author’s knowledge, no attempt has been made at multiple nephron bioprinting. With the upscale 
of the number of nephrons being printed, more accurate cell seeding techniques may be needed in order to 
selectively coat different tubes with the correct cell types. Furthermore, fully recreating renal function 
would require differentiation between juxtamedullary and cortical nephrons and their functions. This 
would also require more accurate cell-seeding and differentiation techniques than currently accomplished. 
Multi-material bioprinting may hold the key to unlocking this potential, and the ability to seed region-
specific growth factors into hydrogels before the addition of renal or vascular cells could enable the 
induction of accurate regional physiologies at the nephron and the kidney level.  Ultimately, advances in 
bioprinting technology will pave the way for functional renal tissue printing. 
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